Try our beta test site

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

This study has been terminated.
(Slow accrual)
Sponsor:
Collaborator:
Leadiant Biosciences, Inc.
Information provided by (Responsible Party):
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01878708
First received: May 23, 2013
Last updated: March 2, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2017
  Primary Completion Date: February 2017 (Final data collection date for primary outcome measure)